Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Cancer Research - United States
doi 10.1158/0008-5472.can-15-1313
Full Text
Open PDFAbstract
Available in full text
Date
March 24, 2016
Authors
Publisher
American Association for Cancer Research (AACR)